[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-383768-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-383768-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","engineer-a-double-team-of-short-lived-and-glucose-sensing-bacteria-for-cancer-eradication","Engineer a double team of short-lived and glucose-sensing bacteria for cancer eradication","","Rationally engineered bacteria are explored to overcome safety and efficacy barriers in cancer therapy. The study designs a short-lived strain, mp105, for safe intravenous administration and demonstrates tumor eradication in mice via direct oncolysis, depletion of tumor-associated macrophages, and activation of CD4+ T cell immunity. A glucose-sensing strain, m6001, selectively colonizes solid tumors, clears tumors more efficiently after intratumoral delivery through in-tumor replication and oncolytic activity, and their combined double-team approach improves outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/engineer-a-double-team-of-short-lived-and-glucose-sensing-bacteria-for-cancer-eradication/383768/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/engineer-a-double-team-of-short-lived-and-glucose-sensing-bacteria-for-cancer-eradication/383768.png","ImageObject",300,407,{"name":42,"@type":43},"Connor ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is engineered bacterial therapy for cancer challenging?","Question",{"text":63,"@type":64},"Safety risks from leaky bacterial growth and limited efficacy, especially under intravenous administration, hinder clinical translation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What properties make mp105 suitable for intravenous treatment?",{"text":68,"@type":64},"mp105 is engineered to be short-lived, allowing safe intravenous administration while retaining anticancer activity through direct oncolysis and immune modulation.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the glucose-sensing bacterium m6001 improve tumor clearance?",{"text":72,"@type":64},"m6001 senses environmental glucose and selectively colonizes solid tumors; after intratumoral injection it replicates post-delivery and shows strong oncolytic capacity, clearing tumors more efficiently than mp105 in the described settings.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},383768,1790780833,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":104},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nEngineer a double team of short-lived and glucosesensing bacteria for cancer eradication  \nAuthors  \nYe Jin, Li Fu  \nCorrespondence  \n[yejindrd@gmail.com](yejindrd@gmail.com)  \nIn brief  \nUsing bacteria for cancer therapy is hampered by safety and efficacy. Jin and Fu control the lifespan and tumorselective colonization of bacteria, achieving tumor eradication safely in mice. Reduction of tumor-associated macrophages and direct oncolysis are mechanisms underlying the bacteriamediated cancer treatment.  \nd mp105 is engineered to be short lived and safe for intravenous administration  \nd m6001 is engineered to selectively colonize solid tumors by sensing glucose  \nd The two bacteria deplete tumor-associated macrophages, eliciting T cell immunity  \nd Combination of the two bacteria improves cancer treatment  \nJin & Fu, 2023, Cell Reports Medicine 4, 101043 June 20, 2023 ª 2023 The Author(s) .  \n[https://doi.org/10.1016/j.xcrm.2023.101043](https://doi.org/10.1016/j.xcrm.2023.101043)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nEngineer a double team of short-lived and glucose-sensing bacteria for cancer eradication  \nYe Jin1,3,4,* and Li Fu2  \n1New Portal Limited, 130-132 Des Voeux Road Central, Hong Kong  \n2Guangdong Province Key Laboratory of Regional Immunity and Diseases, Department of Pharmacology and International Cancer Center, Shenzhen University Medical School, Shenzhen University, Shenzhen, China  \n3WeChat: curryjin  \n4Lead contact  \n*Correspondence: [yejindrd@gmail.com](yejindrd@gmail.com)  \n[https://doi.org/10.1016/j.xcrm.2023.101043](https://doi.org/10.1016/j.xcrm.2023.101043)  \nSUMMARY  \nRationally designed and engineered bacteria represent an emerging unique approach for cancer treatment. Here, we engineer a short-lived bacterium, mp105, that is effective against diverse cancer types and safe for intravenous administration. We reveal that mp105 combats cancer by direct oncolysis, depletion of tumorassociated macrophages, and elicitation of CD4+ T cell immunity. We further engineer a glucose-sensing bacterium named m6001 that selectively colonizes solid tumors. When intratumorally injected, m6001 clears tumors more efficiently than mp105 due to its post-delivery replication in tumors and potent oncolytic capacity. Finally, we combine intravenous injection of mp105 and intratumoral injection of m6001, forming a double team against cancer. The double team enhances cancer therapy compared with single treatment for subjects carrying both intratumorally injectable and uninjectable tumors. The two anticancer bacteria and their combination are applicable to different scenarios, turning bacterial therapy for cancer into a feasible solution.  \nINTRODUCTION  \nWhile conventional therapies fail to provide a cure or sustainable control of most cancers, rationally designed bacteria represent a promising unique therapeutic approach and have been attracting increasing attention in the past decades. Engineered bacteria could serve per se as living anticancer agents or as vectors for delivery of genetic cargos against cancers. The most important concern in using bacteria for cancer therapy is safety. Many efforts have been made to kill bacteria to improve safety by methods such as sonication or heating. A problem with these maneuvers is that the integrity and functionality of anticancer agents produced by the bacteria are, to a more or lesser extent, destroyed. Alternatively, bacteria can be genetically modified to preferably or selectively grow in tumor tissues. For instance, auxotrophic bacteria1,2 and bacteria mutated for certain nonessential genes3 have shown increased tumor selectivity. Or, vulnerability of bacteria to immune attack can be manipulated so that the bacteria can be cleared by the immune system when desired.4 All these bacteria are capable of post-delivery reproduction and possess intact anticancer agents and are, therefore, likely to provide better anticancer efficacy compared with killed ones. Despite this progress, t","cbCaib5JQCV73OXV","https://ap.wps.com/l/cbCaib5JQCV73OXV","pdf",6143996,"English","# Summary\n## Engineered bacteria for cancer therapy\n## mp105: short-lived, intravenous safety and mechanisms\n## m6001: glucose-sensing, tumor-selective colonization\n## Double-team strategy and improved treatment","[{\"question\":\"Why is engineered bacterial therapy for cancer challenging?\",\"answer\":\"Safety risks from leaky bacterial growth and limited efficacy, especially under intravenous administration, hinder clinical translation.\"},{\"question\":\"What properties make mp105 suitable for intravenous treatment?\",\"answer\":\"mp105 is engineered to be short-lived, allowing safe intravenous administration while retaining anticancer activity through direct oncolysis and immune modulation.\"},{\"question\":\"How does the glucose-sensing bacterium m6001 improve tumor clearance?\",\"answer\":\"m6001 senses environmental glucose and selectively colonizes solid tumors; after intratumoral injection it replicates post-delivery and shows strong oncolytic capacity, clearing tumors more efficiently than mp105 in the described settings.\"}]","Engineer a double team of short-lived and glucose-sensing bacteria for cancer eradication | PDF",1790259126]